Dosing begins in trial of drug combo for severe fatty liver disease
The first healthy volunteers have been dosed in a Phase 1 clinical trial testing a combination therapy for metabolic dysfunction-associated steatohepatitis (MASH), a severe form…
Marisa Wexler, MS, Senior Science Writer—
Articles by Marisa Wexler
Oregon gets $7.5M US grant to treat HCV with telehealth, peer support
A three-year program in Oregon is receiving a $7.5-million federal grant to improve healthcare for rural residents who use recreational drugs. The program will use…
ALF unveils network to connect living donors with strangers in need
The American Liver Foundation (ALF) is launching a first-of-its kind national database, called the ALF Living Donor Network, to connect people willing to…
Drug combo shrinks liver fat in rats and zebrafish: Study
A combination of pemafibrate and telmisartan, two medications approved in some countries to help manage cardiovascular conditions, may help reduce the buildup of liver fat…
Enrollment complete in 2 Phase 2 trials testing hepatitis B treatment
Enrollment is complete in two Phase 2 clinical trials testing Ausperbio’s AHB-137 in people with chronic hepatitis B, the company said. That “positions us…
Program improves hepatitis C treatment access for new moms
A simple shift in where new mothers receive care is helping the fight against hepatitis C. By bringing infectious disease specialists to a mother’s…
FDA OKs clinical trials to test cell therapy for chronic hepatitis B
The U.S. Food and Drug Administration (FDA) has given Lion TCR the green light to start Phase 1b/2 clinical trials testing LioCyx-M004, the clinical-stage…
Alcohol consumption disrupts protein that controls liver fat: Study
Exposure to excessive alcohol disrupts the activity of a protein that plays a key role in keeping liver fat healthy, a study found. Researchers said…
Gene-editing approach may one day cure chronic hepatitis B: Study
A gene-editing therapy designed to specifically inactivate a hidden genetic blueprint of the hepatitis B virus (HBV) — the cause of hepatitis B —…
New trial data show saroglitazar works to ease liver damage in PBC
One year of treatment with saroglitazar, Zydus Therapeutics’ experimental oral candidate, outperformed a placebo at normalizing markers of liver injury in people with…